Nu Skin Enterprises Inc. (NUS)
STMicroelectronics-NUS Lab Strengthens Low-Power Edge AI Push
STM and NUS launch a four-year lab to advance low-power edge AI for robots, humanoids and drones using local processing and P18 FD-SOI technology.
Nu Skin Enterprises Q2 Earnings Meet Estimates, Revenues Down Y/Y
NUS' second-quarter revenues fall 17.1% and EPS drops 53.5%, while it cuts the 2026 revenue and adjusted EPS outlooks.
Nu Skin Enterprises, Inc. (NUS) Q2 2026 Earnings Call Transcript
Nu Skin Enterprises, Inc. (NUS) Q2 2026 Earnings Call Transcript
Nu Skin Enterprises Q2 Earnings Call Highlights
Nu Skin Enterprises NYSE: NUS reported second-quarter revenue of $320.1 million and adjusted earnings per share of $0.20, as the company continued the rollout of its Prysm iO wellness platform and pursued cost and margin initiatives.
Nu Skin Enterprises (NUS) Matches Q2 Earnings Estimates
Nu Skin Enterprises (NUS) came out with quarterly earnings of $0.2 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.43 per share a year ago.
Nu Skin (NUS) Soars 6.9%: Is Further Upside Left in the Stock?
Nu Skin (NUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Nu Skin Enterprises Q1 Earnings Call Highlights
Nu Skin Enterprises NYSE: NUS reported first-quarter 2026 results that management said were in line with expectations, as the company continued to invest in its Prysm iO wellness platform and emerging-market expansion while navigating macroeconomic pressures on consumers and supply chains.
Nu Skin Enterprises, Inc. (NUS) Q1 2026 Earnings Call Transcript
Nu Skin Enterprises, Inc. (NUS) Q1 2026 Earnings Call Transcript
Nu Skin Enterprises (NUS) Q1 Earnings and Revenues Lag Estimates
Nu Skin Enterprises (NUS) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.23 per share a year ago.
Nu Skin: Patience Is Still Advised
Nu Skin Enterprises trades at a deep value multiple (~3x 2026 EBITDA) but faces persistent core business decline and unproven turnaround catalysts. Guidance disappointed, yet management expects margin expansion and a return to revenue growth by late 2026, with India and Prysm iO launches as key potential drivers. Non-core assets and a net cash-positive balance sheet provide some downside protection, but secular decline in legacy markets remains a major overhang.
Nu Skin Still Has Long-Term Turnaround Potential
Nu Skin is rated a buy, trading at low multiples with turnaround prospects tied to India expansion and Prysm iO device launch. NUS's core MLM business faces structural decline, but new product and market initiatives could stabilize or grow revenue beyond 2026. Prysm iO potential subscription fees may provide incremental revenue not fully reflected in current guidance.
Nu Skin Enterprises Q4 Earnings Lag Estimates, Revenues Down Y/Y
NUS' fourth-quarter earnings and sales miss estimates, with revenues down 16.9% Y/Y and broad declines across key global regions.
